Skip to main content

Press releases | January 10, 2017

Fried Frank acted as counsel to Goldman Sachs as financial advisor to ARIAD Pharmaceuticals Inc. in its sale to Takeda Pharmaceutical Company Limited for approximately US$5.2 billion. The transaction, which is expected to close by the end of February 2017 will allow ARIAD to accelerate its mission to discover, develop and deliver precision therapies to patients with rare cancers.

The Fried Frank team included corporate partner Philip Richter and corporate associate Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.